Literature DB >> 28707730

Complement and contact system activation in acute congestive heart failure patients.

C Suffritti1, E Tobaldini2,3, R Schiavon4, S Strada4, L Maggioni1, S Mehta5, G Sandrone4, E Toschi-Dias6, M Cicardi1, N Montano2,3.   

Abstract

Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 ± 2 versus 104 ± 3% of total pooled plasma, P < 0·01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 ± 3 versus 108 ± 4%, P = 0·03). When the sample was stratified according to clinical outcome, C3 (98 ± 3 versus 104 ± 4%, P = 0·03) and sC5b-9 levels (204 ± 10 versus 230 ± 11 ng/ml, P = 0·03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 ± 14 versus 243 ± 14 ng/ml, P = 0·04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.
© 2017 British Society for Immunology.

Entities:  

Keywords:  complement system; contact system; heart failure; immune system; ventricular function

Mesh:

Substances:

Year:  2017        PMID: 28707730      PMCID: PMC5629426          DOI: 10.1111/cei.13011

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Serum complement activation in congestive heart failure.

Authors:  D J Clark; M W Cleman; S E Pfau; S A Rollins; T M Ramahi; C Mayer; T Caulin-Glaser; E Daher; M Kosiborod; L Bell; J F Setaro
Journal:  Am Heart J       Date:  2001-04       Impact factor: 4.749

Review 2.  Hereditary angio-oedema.

Authors:  Hilary Longhurst; Marco Cicardi
Journal:  Lancet       Date:  2012-02-04       Impact factor: 79.321

3.  Increased muscle sympathetic nerve activity predicts mortality in heart failure patients.

Authors:  Antonio C P Barretto; Amilton C Santos; Robinson Munhoz; Maria U P B Rondon; Fábio G Franco; Ivani C Trombetta; Fabiana Roveda; Luciana N J de Matos; Ana M W Braga; Holly R Middlekauff; Carlos E Negrão
Journal:  Int J Cardiol       Date:  2008-06-26       Impact factor: 4.164

Review 4.  Advances in assay of complement function and activation.

Authors:  Morten Harboe; Ebbe Billmann Thorgersen; Tom Eirik Mollnes
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

5.  Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure.

Authors:  Tímea Gombos; Zsolt Förhécz; Zoltán Pozsonyi; Gábor Széplaki; Jan Kunde; George Füst; Lívia Jánoskuti; István Karádi; Zoltán Prohászka
Journal:  Clin Res Cardiol       Date:  2012-02-29       Impact factor: 5.460

6.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

Review 7.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

Review 8.  Therapeutic control of complement activation at the level of the central component C3.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2015-06-10       Impact factor: 3.144

9.  Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid.

Authors:  M Cugno; M Cicardi; A Agostoni
Journal:  J Allergy Clin Immunol       Date:  1994-05       Impact factor: 10.793

Review 10.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

View more
  1 in total

1.  Serum Proteomic Changes in Dogs with Different Stages of Chronic Heart Failure.

Authors:  Ahmet Saril; Meric Kocaturk; Kazumi Shimada; Akiko Uemura; Emel Akgün; Pinar Levent; Ahmet Tarik Baykal; Alberto Muñoz Prieto; Carlos Fernando Agudelo; Ryou Tanaka; Jose Joaquin Ceron; Jorgen Koch; Zeki Yilmaz
Journal:  Animals (Basel)       Date:  2022-02-16       Impact factor: 2.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.